Metagenomi Therapeutics, Inc. insider trading
Every open-market purchase and sale by Metagenomi Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $23,401 1 trade by 1 insider Insider sales, 5 years $44,077 17 trades by 4 insiders
3 months later: median −12.8% (−14.2% vs S&P 500)
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Metagenomi Therapeutics, Inc.’s insiders pay?
From September 6, 2024 to September 11, 2026, 4 insiders reported 1 open-market purchase and 3 sales not made under a pre-set plan in Metagenomi Therapeutics, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Irish Jian | See Remarks | 0 | — | — | 1 | — | June 9, 2025 |
| Reid Laurence | Director | 1 | — | — | 0 | — | September 11, 2026 |
| Thomas Brian C. | Chief Executive Officer | 0 | — | — | 1 | — | June 9, 2025 |
| Wapnick Pamela | Chief Financial Officer | 0 | — | — | 1 | — | September 6, 2024 |
← Back to Metagenomi Therapeutics, Inc. · Funds · Politicians